bioMérieux S.A.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| BIM.PA | QGEN | ICLR | 300463.SZ | 300244.SZ | DIA.MI | |
|---|---|---|---|---|---|---|
| Market cap | 11.13B | 10.50B | 15.22B | 5.55B | 13.78B | 4.02B |
| P/E (TTM) | 24.2 | 25.8 | 81.2 | — | 28.6 | 30.0 |
| Forward P/E | 20.1 | 19.5 | 17.5 | 10.6 | 31.3 | 18.8 |
| Price/book | 2.6 | 3.1 | 1.7 | 0.9 | 2.0 | 2.8 |
| Dividend yield | 1.00% | 0.69% | — | — | 1.69% | 1.58% |
| 1-year change | −7.35% | +18.04% | +26.94% | −23.74% | +26.44% | +36.24% |
| Today | −3.17% | +0.89% | −0.32% | +1.32% | +6.73% | −0.71% |
The closest companies by business and industry (Diagnostics & Research). Prices may be delayed up to 15 min.
Latest news
All BIM.PA news ›bioMérieux S.A. (BMXXY) Q3 2026 Sales/Trading Call Transcript
bioMérieux S.A. (BMXXY) Q3 2026 Sales/Trading Call November 3, 2026 8:00 AM EST Aymeric Fichet - Head of Investor RelationsPierre Boulud - Chief Executive OfficerGuillaume Bouhours - Executive VP of Finance, Purchasing and Information…
BioMérieux Reports 10 Percent Q3 Sales Growth
BioMérieux Q3 Sales up 10 Percent, Lifted by Non-Respiratory MDx Tests GenomeWeb BioMérieux Q3 Sales up 10 Percent, Lifted by Non-Respiratory MDx Tests
Biomérieux third-quarter sales grew more than expected
(Corrects consensus figure to million from billion) Nov 3 (Reuters) – French biotechnology firm Biomérieux reported on Tuesday a better-than-expected organic sales growth in the third quarter, helped by a 13% increase in sales from…
Key facts: bioMerieux SA BIOFIRE sales up 25%; vaginitis panel in 2027
TradingView Key facts: bioMerieux SA BIOFIRE sales up 25%; vaginitis panel in 2027 - bioMerieux (BIM) said BIOFIRE Non-Respiratory panel sales rose 25% in Q3, boosted by demand for its gastrointestinal test amid a U.S. cyclospor
WHO grants bioMérieux’s Ebola panel emergency listing amid ongoing Bundibugyo outbreak
BioFire is the fifth diagnostic to receive an EUL from the WHO since the Bundibugyo outbreak in Central Africa was declared a public emergency in May 2026. The World Health Organization (WHO) has granted bioMérieux’s panel for detecting…
BioMerieux Special Pathogens Panel Gets WHO Emergency Listing
BioMérieux Panel Gets WHO Emergency Use Listing to Support Ebola Response GenomeWeb BioMérieux Panel Gets WHO Emergency Use Listing to Support Ebola Response
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- freedom959.net1
- genomeweb.com1
- seekingalpha.com1
- tradingview.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 4 articles, not a forecast.